SCHEMBL17508286

SCHEMBL17508286

O=Cc1ccc(C(F)(F)c2ccccc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
CYP2A6 P11509 2/20 0.54
TSHR P16473 1/20 0.42
HSD17B10 Q99714 1/20 0.39
ALDH5A1 P51649 1/20 0.39
ABAT P80404 1/20 0.39
PTPN1 P18031 1/20 0.39
KIF11 P52732 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA5A P35218 1/20 0.38
CA9 Q16790 1/20 0.38
DRD1 P21728 3/20 0.37
KMT2A Q03164 1/20 0.37
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DRD2 P14416 1/20 0.36
DRD4 P21917 1/20 0.36
DRD5 P21918 1/20 0.36
DRD3 P35462 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6852179 0.91 CYP2A6 (0.46) ALDH1A1CYP2A6HSD17B10ALDH5A1ABAT
SCHEMBL16626101 0.87 ALDH1A1 (0.54) ALDH1A1CYP2A6TSHRHSD17B10ALDH5A1
SCHEMBL6849342 0.84 ALDH1A1 (0.42) ALDH1A1CYP2A6KIF11DRD1POLB
SCHEMBL9883874 0.82 ALDH1A1 (0.59) ALDH1A1CYP2A6HSD17B10ALDH5A1ABAT
SCHEMBL29572467 0.82 ALDH1A1 (0.48) ALDH1A1CYP2A6TSHRKMT2APOLB
SCHEMBL28376764 0.82 ALDH1A1 (0.48) ALDH1A1CYP2A6TSHRKMT2APOLB
SCHEMBL6852237 0.79 MEN1 (0.41) ALDH1A1CYP2A6TSHRHSD17B10ALDH5A1
SCHEMBL9883872 0.78 ALDH1A1 (0.54) ALDH1A1CYP2A6HSD17B10ALDH5A1ABAT
SCHEMBL6925390 0.78 ALDH1A1 (0.54) ALDH1A1CYP2A6HSD17B10ALDH5A1ABAT
SCHEMBL2143877 0.78 ALDH1A1 (0.54) ALDH1A1CYP2A6TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
US-20220185815-A1 PYRROLOPYRAZOLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2022-06-16 US disclosed
WO-2016019588-A1 OXACAZONE COMPOUNDS TO TREAT CLOSTRIDIUM DIFFICILE THE BROAD INSTITUTE, INC. (US) 2016-02-11 WO disclosed
WO-2016019588-A1 OXACAZONE COMPOUNDS TO TREAT CLOSTRIDIUM DIFFICILE THE BROAD INSTITUTE, INC. (US) 2016-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220185815-A1 PYRROLOPYRAZOLE DERIVATIVE PTDSS1, PTDSS2, SMPD1 ALDH1A1 2761/4885CYP2A6 3070/4885TSHR 4443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.